Neovacs SA (FR:ALNEV) has released an update.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Neovacs SA, a French biotech firm focusing on inflammatory and autoimmune diseases, has partnered with CNRS’s UTCBS to develop mRNA vaccine delivery methods for asthma treatment. The collaboration, which Neovacs will exclusively fund for 100 k€, aims to create lipid formulations for human and veterinary vaccines. The company is recognized by the CNRS for its R&D efforts in the field of active immunotherapy through its kinoid® technology platform.
For further insights into FR:ALNEV stock, check out TipRanks’ Stock Analysis page.